Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

Leuk Res. 2020 Dec:99:106472. doi: 10.1016/j.leukres.2020.106472. Epub 2020 Nov 5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Activin Receptors, Type II / therapeutic use
  • Aged
  • Anemia, Sideroblastic / drug therapy*
  • Anemia, Sideroblastic / mortality
  • Anemia, Sideroblastic / therapy
  • Azacitidine / therapeutic use
  • Disease Progression
  • Erythrocyte Transfusion
  • Erythropoietin / blood
  • Female
  • Ferritins / blood
  • Follow-Up Studies
  • Hematinics / therapeutic use*
  • Humans
  • Immunoglobulin Fc Fragments / therapeutic use
  • Kaplan-Meier Estimate
  • Lenalidomide / therapeutic use
  • Male
  • Proportional Hazards Models
  • Recombinant Fusion Proteins / therapeutic use
  • Salvage Therapy*
  • Treatment Failure

Substances

  • EPO protein, human
  • Hematinics
  • Immunoglobulin Fc Fragments
  • Recombinant Fusion Proteins
  • Erythropoietin
  • Ferritins
  • luspatercept
  • Activin Receptors, Type II
  • Lenalidomide
  • Azacitidine